Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enzastaurin - Aytu BioPharma/ Denovo Biopharma

Drug Profile

Enzastaurin - Aytu BioPharma/ Denovo Biopharma

Alternative Names: AR-101 - Aytu BioPharma; DB 102; Enzastaurin hydrochloride; Kinenza; LY-317615

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Aytu BioPharma; Denovo Biopharma; Eli Lilly and Company
  • Class Antineoplastics; Indoles; Piperidines; Pyridines; Pyrrolidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Protein kinase C beta inhibitors; Protein-serine-threonine kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Diffuse large B cell lymphoma; Ehlers-Danlos syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma; Ehlers-Danlos syndrome; Glioblastoma
  • Preclinical Connective tissue disorders
  • Discontinued Brain cancer; Breast cancer; Cancer; Colorectal cancer; Follicular lymphoma; Lung cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 29 Feb 2024 Denovo Biopharma completes the phase-III ENGAGE trial in Glioblastoma (Adjuvant therapy, First-line therapy) in USA, Canada and China (NCT03776071)
  • 14 Oct 2022 Aytu Biopharma suspends the phase III PREVEnt trial in Ehlers Danlos Syndrome (Adjunctive treatment, Prevention, In adults) in France, Netherlands, Sweden (PO, Tablet), due to indefinite hold by the company (NCT05463679) (EudraCT2021-006574-23)
  • 12 Jul 2022 Denovo Biopharma completes the phase III ENGINE trial for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in China and USA (PO) (NCT03263026)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top